Please use this identifier to cite or link to this item: https://doi.org/10.1158/1535-7163.MCT-13-0056
Title: Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model
Authors: Sia, K.C.
Huynh, H.
Chung, A.Y.F.
Ooi, L.L.P.J.
Lim, K.H.
Hui, K.M. 
Lam, P.Y.P.
Issue Date: Aug-2013
Citation: Sia, K.C., Huynh, H., Chung, A.Y.F., Ooi, L.L.P.J., Lim, K.H., Hui, K.M., Lam, P.Y.P. (2013-08). Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model. Molecular Cancer Therapeutics 12 (8) : 1651-1664. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-13-0056
Abstract: Gene regulation of many key cell-cycle players in S-, G2 phase, and mitosis results from transcriptional repression in their respective promoter regions during theG0 andG1 phases of cell cycle. Within these promoter regions are phylogenetically conserved sequences known as the cell-cycle-dependent element (CDE) and cellcycle genes homology regions (CHR) sites. Thus, we hypothesize that transcriptional regulation of cell-cycle regulation via the CDE/CHR region together with liver-specific apolipoprotein E (apoE)-hAAT promoter could bring about a selective transgene expression in proliferating human hepatocellular carcinoma. We show that the newly generated vector AH-6CC-L2C could mediate hepatocyte-targeted luciferase gene expression in tumor cells and freshly isolated short-term hepatocellular carcinoma cultures from patient biopsy. In contrast, normal murine and human hepatocytes infected with AH-6CC-L2C expressed minimal or low luciferase activities. In the presence of prodrug 5-fluorocytosine (5-FC), AH-6CC-L2C effectively suppressed the growth of orthotopic hepatocellular carcinoma patient-derived xenograft mouse model via the expression of yeast cytosine deaminase (yCD) that converts 5-FC to anticancer metabolite 5-fluoruracil. More importantly, we show that combination treatment of AH-6CC-L2C with an EZH2 inhibitor, DZNep, that targets EpCAMpositive hepatocellular carcinoma, can bring about a greater therapeutic efficacy compared with a single treatment of virus or inhibitor. Our study showed that targeting proliferating human hepatocellular carcinoma cells through the transcriptional control of therapeutic gene could represent a feasible approach against hepatocellular carcinoma. Mol Cancer Ther; 12(8); 1651-64. © 2013 AACR.
Source Title: Molecular Cancer Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/110611
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-13-0056
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

8
checked on Nov 13, 2018

WEB OF SCIENCETM
Citations

7
checked on Oct 22, 2018

Page view(s)

29
checked on Nov 2, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.